# Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

> **NCT07334119** · PHASE1 · RECRUITING · sponsor: **Myeloid Therapeutics** · enrollment: 60 (estimated)

## Conditions studied

- HER2-Expressing Solid Tumors

## Interventions

- **DRUG:** MT-304
- **DRUG:** MT-304 + Nivolumab

## Key facts

- **NCT ID:** NCT07334119
- **Lead sponsor:** Myeloid Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-25
- **Primary completion:** 2027-01-31
- **Final completion:** 2028-03-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07334119

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07334119, "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT07334119. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*